Joseph A. Sparano

Tisch Cancer Institute

Biochemistry, Genetics and Molecular Biology · Life Sciences

90h-index37.5kcitations788works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Breast Cancer Treatment Studies(210), Cancer Treatment and Pharmacology(158), HER2/EGFR in Cancer Research(148), Advanced Breast Cancer Therapies(116), Lymphoma Diagnosis and Treatment(99)

Publications779 total

Racial disparity in pro-metastatic tumor microenvironment in treatment naïve breast cancer
npj Breast Cancer·2026Open Access
Data from A Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of a Folate Receptor Alpha Vaccine in Patients with Triple-Negative Breast Cancer
2026Open Access
Supplementary Data 1 from A Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of a Folate Receptor Alpha Vaccine in Patients with Triple-Negative Breast Cancer
2026Open Access
Supplementary Table 1 from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
2025Open Access
Supplementary Figure 1 from Phase I Trial of the Multi-kinase Inhibitor Cabozantinib, a CYP3A4 Substrate, plus CYP3A4-Interacting Antiretroviral Therapy in People Living with HIV and Cancer (AMC-087)
2025Open Access
A Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of a Folate Receptor Alpha Vaccine in Patients with Triple-Negative Breast Cancer
Clinical Cancer Research·2025· 1 citedOpen Access
Machine Learning–Based Prediction of Distant Recurrence Risk and Ribociclib Treatment Effect in HR+/HER2− Early Breast Cancer Using Real-World and NATALEE Data
Clinical Cancer Research·2025· 1 citedOpen Access
Radiotherapy With a 12-Gene Expression Assay for Ductal Carcinoma In Situ
JAMA Oncology·2025Open Access
Demonstrating long-term value in older patients (pts): Cost-effectiveness of ribociclib (RIB) in hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) early breast cancer (EBC).
JCO Oncology Practice·2025
600- vs 400-mg First-Line Ribociclib in Hormone Receptor–Positive/ <i>ERBB2</i> -Negative Advanced Breast Cancer
JAMA Oncology·2025· 2 citedOpen Access
Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/HER2-negative breast cancer
Annals of Oncology·2025· 1 citedOpen Access
Ambient air pollution and mortality in older patients with breast cancer
JNCI Journal of the National Cancer Institute·2025· 3 cited
Mutations in MLL3 promote breast cancer progression via HIF1α-dependent intratumoral recruitment and differentiation of regulatory T cells
Immunity·2025· 5 citedOpen Access
Detection of TMEM Doorways and Their Activity Required for Metastasis
2025
CD20-bearing extracellular vesicles are associated with prognostic biomarkers of patients with AIDS-NHL
Scientific Reports·2025Open Access
Quality of Life Among Patients With Ductal Carcinoma In Situ
JAMA Network Open·2025Open Access
Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial
UNC Libraries·2025Open Access
Abstract P1-04-16: Racial Disparities in the Pro-Metastatic Tumor Microenvironment of Treatment-Naive Breast Cancer
Clinical Cancer Research·2025
Abstract P3-10-20: Phase II study of talazoparib, a PARP inhibitor, in HER2- metastatic breast cancer (MBC) with a somatic BRCA1/2 mutation identified in cell-free DNA or tumor tissue genotyping
Clinical Cancer Research·2025
Abstract P3-01-02: Impact of race, socioeconomic status and clinicopathological features on clinical outcomes in triple negative breast cancer in the ECOG-ACRIN EA1131 trial
Clinical Cancer Research·2025
page 1 of 39Next →

Frequent Co-authors

Nancy E. Davidson(12), Sunil Badve(11), George W. Sledge(10), Edith A. Perez(9), Robert J. Gray(8), William C. Wood(8), Sibylle Loibl(7), Sylvia Adams(7), Lori J. Goldstein(7), Giuseppe Viale(6), Della Makower(6), Kathleen I. Pritchard(6), Soonmyung Paik(6), Silvana Martino(6), Antonio C. Wolff(6), Miguel Martín(6), Carsten Denkert(5), Sandra Demaria(5), Frederick L. Baehner(5), Charles E. Geyer(5)